How to Use TABA After an NIH SBIR Phase I Award

Mike Hull • September 3, 2026

A Phase I award proves that NIH sees merit in the proposed technical work. It does not automatically answer the commercial questions needed for Phase II, licensing, strategic partnering, or private financing. TABA can be used to close some of those gaps.

First, Confirm Eligibility and Institute-Specific Process

NIH states that TABA is preferably requested in the original application, but recipients may request TABA funding after award through an administrative supplement. The awarding Institute or Center has discretion to accept or reject the request, so the first practical step is to contact the appropriate NIH Small Business Program Manager or grants contact before preparing a supplement.

Second, Define One or More Concrete Commercialization Needs

The strongest request is tied directly to decisions the company must make during or immediately after Phase I.


  • Which indication or beachhead market should be prioritized?
  • What is the likely FDA pathway and what evidence will be required?
  • What competitors and alternative approaches define the commercial landscape?
  • What IP risks or white-space opportunities should be evaluated?
  • What development milestones will make the program ready for Phase II or private capital?
  • Which strategic partners, licensees, customers, or investors are most relevant?

Third, Build a Deliverable-Driven Scope of Work

NIH guidance emphasizes describing the vendor, scope of work, and use of funds. A practical TABA scope should specify tasks, deliverables, schedule, and price rather than rely on broad advisory language.


  • Commercial landscape and competitor matrix
  • Regulatory pathway memo
  • Customer/stakeholder discovery plan and findings
  • Commercialization roadmap with prioritized milestones
  • Partner or financing target map
  • Manufacturing, cybersecurity, or other specialized development plan

Fourth, Connect Taba to Phase II Readiness

The most useful TABA work changes what the company does next. For example, market findings might change the initial indication; regulatory analysis might alter the validation study; partner feedback might define the data package required before outreach. Those connections should be explicit.

Administrative Supplement Basics

NIH's SEED FAQ indicates that post-award TABA can be requested through an administrative supplement and is subject to Institute or Center discretion and NIH prior-approval requirements. Confirm the exact submission instructions, budget treatment, timing, and required attachments with your awarding component before submitting.

BYB Takeaway

Treat TABA as a targeted de-risking budget, not an extra consulting allowance. The goal is to spend a small amount now to make a better Phase II, regulatory, partnering, or financing decision later.

Before submitting a TABA supplement, define the exact question, vendor deliverable, and decision the work will support.

Source notes

NIH SEED TABA FAQ: https://seed.nih.gov/faqs

NIH SEED, Creating a TABA request: https://seed.nih.gov/node/4222

NIH Notice NOT-OD-26-075: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-075.html

How to Commercialize University Research

By Mike Hull • September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

What Is a Biotech Commercialization Plan?

By Mike Hull • September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

How Much Validation Do You Need Before Raising Capital?

By Mike Hull • September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

License Your Technology or Start a Biotech Company?

By Mike Hull • September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.

The Bootstrap Score™

By Mike Hull • September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The Commercialization Gap™

By Mike Hull • September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.

The Valley of Dilution™

By Mike Hull • September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

The Bootstrap Flywheel™

By Mike Hull • September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

Biotech Funding Sequence: What Money Should You Raise First?

By Mike Hull • September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

When Should a Biotech Startup Raise Venture Capital?

By Mike Hull • September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.